Gregory A Wiseman

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    G A Wiseman
    Mayo Clinic and Foundation, Division of Nuclear Medicine, Charlton Building 1 223, 200 First Street S W, Rochester, MN 55905, USA
    Crit Rev Oncol Hematol 39:181-94. 2001
  2. ncbi request reprint Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN, USA
    Cancer Biother Radiopharm 20:185-8. 2005
  3. ncbi request reprint Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
    Gregory A Wiseman
    Division of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:4336-42. 2002
  4. ncbi request reprint Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials
    Gregory A Wiseman
    Nuclear Medicine, Department of Radiology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Nucl Med 44:465-74. 2003
  5. ncbi request reprint Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer Biother Radiopharm 18:165-78. 2003
  6. ncbi request reprint Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
    G A Wiseman
    Department of Radiology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Eur J Nucl Med 27:766-77. 2000
  7. ncbi request reprint Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer Biother Radiopharm 18:253-8. 2003
  8. ncbi request reprint Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
    G A Wiseman
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 5:3281s-3286s. 1999
  9. ncbi request reprint Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma
    Gregory A Wiseman
    Division of Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 94:1349-57. 2002
  10. ncbi request reprint 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients
    Dimitrios Karantanis
    Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Nucl Med Commun 28:834-41. 2007

Detail Information

Publications53

  1. ncbi request reprint Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    G A Wiseman
    Mayo Clinic and Foundation, Division of Nuclear Medicine, Charlton Building 1 223, 200 First Street S W, Rochester, MN 55905, USA
    Crit Rev Oncol Hematol 39:181-94. 2001
    ..An important secondary objective was to determine if radiation dosimetry prior to 90Y Zevalin administration is required for safe treatment in this patient population...
  2. ncbi request reprint Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN, USA
    Cancer Biother Radiopharm 20:185-8. 2005
    ..This retrospective analysis was conducted to determine the number of patients achieving long-term durable responses with (90)Y ibritumomab tiuxetan treatment...
  3. ncbi request reprint Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
    Gregory A Wiseman
    Division of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:4336-42. 2002
    ..The incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 33%, 13%, and 3%, respectively. Reduced-dose ibritumomab tiuxetan is safe and well tolerated and has significant clinical activity in this patient population...
  4. ncbi request reprint Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials
    Gregory A Wiseman
    Nuclear Medicine, Department of Radiology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Nucl Med 44:465-74. 2003
    ..Dosimetry and pharmacokinetic data from 4 clinical trials of (90)Y-ibritumomab tiuxetan RIT for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) were combined and assessed for correlations with toxicity data...
  5. ncbi request reprint Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer Biother Radiopharm 18:165-78. 2003
    ..These correlations were not consistent across the total patient population, and therefore, could not be exploited to predict hematologic toxicity...
  6. ncbi request reprint Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
    G A Wiseman
    Department of Radiology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Eur J Nucl Med 27:766-77. 2000
    ..The only toxicity of note is hematologic and is not correlated to red marrow radiation absorbed dose estimates or T(1/2), reflecting that hematologic toxicity is dependent on bone marrow reserve in this heavily pretreated population...
  7. ncbi request reprint Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer Biother Radiopharm 18:253-8. 2003
    ..Radiation absorbed doses to organs and marrow were within a safe range following administration of 0.4 mCi/kg (90)Y Zevalin...
  8. ncbi request reprint Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
    G A Wiseman
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 5:3281s-3286s. 1999
    ..The overall response rate was 64% in the first trial and 67% in the later trial. Phase II and III trials are ongoing...
  9. ncbi request reprint Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma
    Gregory A Wiseman
    Division of Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 94:1349-57. 2002
    ..The purpose of this trial was to perform (111)In-Zevalin imaging in patients with rituximab-refractory tumors to determine normal organ dosimetry...
  10. ncbi request reprint 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients
    Dimitrios Karantanis
    Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Nucl Med Commun 28:834-41. 2007
    ..To determine the value of F-FDG PET/CT in the different manifestations of primary central nervous system lymphoma (PCNSL) in HIV-negative patients...
  11. ncbi request reprint Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia
    Vilmarie Rodriguez
    Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 47:1583-92. 2006
    ..Thus, in adolescents and adults, 153Sm-EDTMP may provide a relatively simple and effective means for using irradiation to eliminate AML within the marrow...
  12. doi request reprint A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    Angela Dispenzieri
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 85:409-13. 2010
    ..Addition of high-dose (153)Sm-EDTMP to melphalan conditioning appears to be safe, well tolerated, and worthy of further study in the context of novel agents and in the Phase III setting...
  13. ncbi request reprint Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
    Thomas E Witzig
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:1804-10. 2007
    ..Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined...
  14. doi request reprint Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies
    Trond Velde Bogsrud
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Nucl Med Commun 32:245-51. 2011
    ....
  15. doi request reprint 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma
    Trond Velde Bogsrud
    Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Thyroid 18:713-9. 2008
    ..The objective of this study was to investigate the potential contribution of 18F-FDG PET to the clinical management of patients with ATC...
  16. ncbi request reprint Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma
    Thomas E Witzig
    Division of Internal Medicine and Hematology and the Department of Radiology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 21:1263-70. 2003
    ..This study presents the safety data from 349 patients in five studies of outpatient treatment with (90)Y ibritumomab tiuxetan...
  17. ncbi request reprint Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    Thomas E Witzig
    Division of Internal Medicine and Hematology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, 60 Stabile Building, Rochester, MN 55905, USA
    J Clin Oncol 20:2453-63. 2002
    ....
  18. doi request reprint The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma
    Trond Velde Bogsrud
    Division of Nuclear Medicine, Department of Radiology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    Mol Imaging Biol 12:547-53. 2010
    ..To explore the prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET) in patients with suspected residual or recurrent medullary thyroid carcinoma (MTC)...
  19. ncbi request reprint Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland
    Dimitrios Karantanis
    Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Nucl Med 48:896-901. 2007
    ..Our purpose was to determine the clinical significance of diffusely increased (18)F-FDG uptake in the thyroid gland as an incidental finding on PET/CT...
  20. ncbi request reprint Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN, USA
    Clin Lymphoma Myeloma 7:514-7. 2007
    ..Patients weighing > 80 kg with platelet counts of >or= 150 x 10(9)/L receive a lower dose per unit of body weight. We evaluated whether this influences the safety or efficacy of treatment...
  21. doi request reprint 18F-FDG PET and PET/CT in Burkitt's lymphoma
    Dimitrios Karantanis
    Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Eur J Radiol 75:e68-73. 2010
    ..To explore the value of (18)F fluorodeoxy-glucose (FDG) positron emission tomography (PET) in Burkitt's lymphoma...
  22. ncbi request reprint Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma
    Stephen M Ansell
    Divisions of Hematology and Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 20:3885-90. 2002
    ..The goal of this analysis was to evaluate the therapy given to patients who relapsed after 90Y ibritumomab tiuxetan...
  23. doi request reprint The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma
    Dimitrios Karantanis
    Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 8:94-9. 2008
    ..The purpose of this study was to assess the value of FDG PET/CT in this aggressive type of non-Hodgkin lymphoma...
  24. ncbi request reprint The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT
    Trond V Bogsrud
    Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Nucl Med Commun 28:373-81. 2007
    ....
  25. ncbi request reprint Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT
    Dimitrios Karantanis
    Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN, USA
    J Comput Assist Tomogr 31:800-5. 2007
    ..To demonstrate 3 cases of artifactual focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of any computed tomographic (CT) abnormality...
  26. pmc Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma
    Laura E Moreno-Luna
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cardiovasc Intervent Radiol 36:714-23. 2013
    ..This retrospective case-control study compared the outcomes and safety of TARE versus TACE in patients with unresectable HCC...
  27. ncbi request reprint Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia
    Vilmarie Rodriguez
    Division of Pediatric Hematology Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Pediatr Transplant 9:122-6. 2005
    ..She achieved engraftment on day +23. Three years after transplantation, she continues to have complete remission. Samarium and melphalan constitute a well-tolerated regimen with potential antileukemic activity...
  28. ncbi request reprint Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma
    Dimitrios Karantanis
    Department of Radiology, Division of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA
    Clin Nucl Med 32:271-4. 2007
    ..The purpose of this case report was to document the potential usefulness of F-18 FDG-PET in the detection of occult systemic involvement in PCNSL...
  29. ncbi request reprint Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy
    Terry E Justice
    Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 107:433-8. 2006
    ..Many patients eventually relapse after radioimmunotherapy (RIT) and require additional treatment. The goal of this study was to determine the safety and efficacy of external beam radiation therapy (EBRT) delivered after RIT...
  30. ncbi request reprint Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
    Malik E Juweid
    Department of Radiology, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 25:571-8. 2007
    ..To develop guidelines for performing and interpreting positron emission tomography (PET) imaging for treatment assessment in patients with lymphoma both in clinical practice and in clinical trials...
  31. ncbi request reprint Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation
    W J Hogan
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Bone Marrow Transplant 28:305-9. 2001
    ..The patient progressed from being wheelchair-bound to independent ambulation. An aggressive approach should be considered in patients with POEMS syndrome in whom standard therapeutic measures fail...
  32. ncbi request reprint Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
    Malik E Juweid
    Department of Radiology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 23:4652-61. 2005
    ....
  33. ncbi request reprint Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?
    V Fatourechi
    Division of Endocrinology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Thyroid 10:573-7. 2000
    ..In conclusion: (1) 13% of 117 PTS demonstrated abnormal foci of 131I uptake not seen on pretherapy scans and (2) PTS changed management strategy in 9% of the studied patients...
  34. ncbi request reprint Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO(2) response to 100% oxygen, and brain uptake after (99m)Tc MAA lung scanning
    M J Krowka
    Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, USA
    Chest 118:615-24. 2000
    ..Abnormal extrapulmonary uptake of (99m)Tc macroaggregated albumin (MAA) after lung perfusion is common...
  35. doi request reprint Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma
    P B Johnston
    Division of Hematology Blood and Marrow Transplantation, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 41:919-25. 2008
    ..Validation is ongoing in larger prospective trials. Future directions include the potential incorporation of post-ASCT therapy, such as radiation therapy or maintenance antibody therapy, for patients with positive pre-ASCT PET scans...
  36. ncbi request reprint Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods
    V F Fairbanks
    Department of Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood Cells Mol Dis 22:169-86; discussion 186a-186g. 1996
    ..No cases of "stress erythrocytosis" or Gaisbock Syndrome were encountered among the 119 cases reviewed...
  37. ncbi request reprint Systolic and diastolic cardiac dysfunction early after the initiation of doxorubicin therapy: significance of gender and concurrent mediastinal radiation
    I P Clements
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Nucl Med Commun 23:521-7. 2002
    ..Male gender and concurrent mediastinal irradiation were independent influences, but doxorubicin dose and the use of other cytotoxic agents were not associated with worse cardiac dysfunction...
  38. ncbi request reprint Evaluation of macroaggregated albumin particle sizes for use in pulmonary shunt patient studies
    J C Hung
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, MN 55905, USA
    J Am Pharm Assoc (Wash) 40:46-51. 2000
    ..To assess commercial macroaggregated albumin (MAA) reagent kits for compliance with particle-size parameters needed for proper clinical evaluation of pulmonary shunts (right-to-left)...
  39. ncbi request reprint A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    A Dispenzieri
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leukemia 19:118-25. 2005
    ..Overall response rate was 94% including seven very good partial responses and five complete responses. Addition of 153Sm EDTMP to melphalan conditioning appears to be safe, well-tolerated and worthy of further study...
  40. ncbi request reprint Metastatic malignant melanoma
    S N Markovic
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    G Ital Dermatol Venereol 144:1-26. 2009
    ..Herein we review the state-of-the-art in metastatic melanoma diagnostics and therapeutics with particular emphasis on multi-disciplinary clinical management...
  41. ncbi request reprint Assessment of Lymphoma Therapy Using (18)F-FDG PET
    Val J Lowe
    PET Imaging, Department of Radiology, Mayo Clinic Rochester, Minnesota 55905, USA
    J Nucl Med 43:1028-30. 2002
  42. ncbi request reprint Sensitivity and utility of parathyroid scintigraphy in patients with primary versus secondary and tertiary hyperparathyroidism
    Tuan H Pham
    Department of Surgery, Mayo Clinic, 200 Second Street SW, Rochester, Minnesota 55901, USA
    World J Surg 30:327-32. 2006
    ..Moreover, we evaluated (1) the sensitivity of PS in detecting enlarged glands, and (2) PS detectability as a function of gland weight...
  43. pmc Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
    Ivana N M Micallef
    Mayo Clinic Rochester, Rochester, MN, USA
    Blood 118:4053-61. 2011
    ..ER-CHOP is well tolerated and results appear promising as a combination therapy. This study was registered at www.clinicaltrials.gov as #NCT00301821...
  44. doi request reprint Hepatic vein tumor thrombus as a risk factor for excessive pulmonary deposition of microspheres during TheraSphere therapy for unresectable hepatocellular carcinoma
    Chad J Fleming
    Department of Radiology, Division of Vascular and Interventional Radiology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Vasc Interv Radiol 20:1460-3. 2009
    ..To evaluate the impact of identifiable hepatic vein tumor thrombus on the ability to safely deliver TheraSphere (yttrium 90-containing glass microspheres) for the treatment of hepatocellular carcinoma (HCC)...
  45. doi request reprint Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial
    Gregory A Wiseman
    Department of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota, USA
    J Nucl Med 50:1448-54. 2009
    ..The present study was designed to provide a prospective confirmation of the performance of (123)I-MIBG scintigraphy for the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma...
  46. pmc Malignant melanoma in the 21st century: the emerging molecular landscape
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 83:825-46. 2008
    ..We review the emerging molecular landscape of melanoma and its implications for better management of patients with melanoma...
  47. ncbi request reprint High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases
    Peter M Anderson
    Department of Pediatrics, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 20:189-96. 2002
    ..Because the dose-limiting toxicity of (153)Sm-EDTMP is thrombocytopenia, a dose-escalation trial using peripheral-blood progenitor cells (PBPCs) or marrow support was conducted to treat metastatic bone cancer...
  48. ncbi request reprint Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer
    Vahab Fatourechi
    Division of Endocrinology, Metabolism, Nutrition, and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 87:1521-6. 2002
    ..Therefore, widespread use of empiric RAI therapy for such patients who have a large tumor burden should not be encouraged...
  49. ncbi request reprint Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody
    Henry N Wagner
    School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland 21205, USA
    J Nucl Med 43:267-72. 2002
    ..Understanding the unique properties of this novel radioimmunoconjugate will facilitate its safe and effective use...
  50. ncbi request reprint Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma
    Christos Emmanouilides
    Division of Hematology Oncology, University of California, Los Angeles, CA, USA
    Cancer Biother Radiopharm 22:684-91. 2007
    ..We analyzed data from clinical trials of yttrium-90-ibritumomab tiuxetan (Zevalin); Biogen Idec, Cambridge, MA) to determine its safety and efficacy in older patients with NHL...
  51. ncbi request reprint Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma
    Christos Emmanouilides
    Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA 90095 1678, USA
    Leuk Lymphoma 47:629-36. 2006
    ..The quality of disease remissions obtained when (90)Y ibritumomab tiuxetan is administered after first relapse appears to be comparable with that observed with most chemotherapy regimens in first-relapse patients...
  52. ncbi request reprint Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma
    Peter M Anderson
    Pediatrics Unit, M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 11:6895-900. 2005
    ..The strategy of radioactive drug binding to a target followed by a radiosensitizer may provide synergy and improved response rate...
  53. pmc A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma
    Ian D Davis
    Ludwig Institute for Cancer Research, Victoria, Australia
    Cancer Immun 7:13. 2007
    ..In conclusion, repeated intravenous doses of up to 50 mg/m(2) of cG250 are safe. Furthermore cG250 has a long half-life and targets clear cell RCC effectively...